Jun 30, 2025 8:00am EDT Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
Jun 11, 2025 4:06pm EDT Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Jun 11, 2025 8:30am EDT Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
May 29, 2025 8:00am EDT Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
May 28, 2025 8:00am EDT Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
May 13, 2025 4:06pm EDT Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025 8:00am EDT Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
Mar 13, 2025 4:07pm EDT Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
